source
- Daiichi Sankyo posts 'extraordinary loss' of nearly $1BDaiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an "extraordinary loss" of 149.4 billion Japanese yen ($950 million) after overpromising deman…Endpoints · 2mo ago↗ source
- Lilly to invest extra $4.5B across Indiana manufacturingThe Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.BioPharma Dive · 2mo ago↗ source
- FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...